Ilmarinen P, et al. - In an unselected cohort of consecutive patients with adult-onset asthma, researchers assessed the prevalence and characteristics of patients eligible to anti-IL-5 treatment and severe asthma in Seinäjoki Adult Asthma Study (SAAS), which is a 12-year follow-up study of patients with new-onset adult asthma. They found that for severe asthma and for anti-IL-5 treatment, 5.9% and 2% patients respectively, fulfilled criteria and were qualified. Severe asthmatics showed the following characteristics than anti-IL-5-eligible patients: more often being current smokers at diagnosis, obese, used higher inhaled corticosteroid dose and had higher blood neutrophils 12 years after diagnosis. The highest number of hospitalizations was observed in severe asthmatics. Both groups were shown to offer a high burden to healthcare. At long-term, lower use of healthcare could be ensured via specifically targeted treatment.